Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.

Sophie TestaPaolo PrandoniOriana PaolettiRossella MorandiniMaurizio TalaClaudia DellanoceMatteo Giorgi-PierfranceschiMonia BettiGian Battista DanziAngelo PanGualtiero Palareti

Published in: Journal of thrombosis and haemostasis : JTH (2020)

DOAC patients treated with antiviral drugs show an alarming increase in DOAC plasma levels. In order to prevent bleeding complications, we believe that physicians should consider withholding DOACs from patients with SARS-CoV-2 and replacing them with alternative parenteral antithrombotic strategies for as long as antiviral agents are deemed necessary and until discharge.

Keyphrases

sars cov
direct oral anticoagulants
atrial fibrillation
venous thromboembolism
coronavirus disease
respiratory syndrome coronavirus
early onset
risk factors
drug induced
case report